Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lacticaseibacillus paracasei LA802
- Development stage
- Unknown
- Lead developer
- PiLeJe
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Buccal
01
Overview
Lacticaseibacillus paracasei LA802 (formerly Lactobacillus paracasei LA 802) is a specific probiotic bacterial strain developed and marketed by the French laboratory PiLeJe. It is a live lactic acid bacterium that has been deposited and registered in the Collection Nationale de Cultures de Microorganismes (CNCM) at the Institut Pasteur. The strain is the primary active component in the Lactibiane Buccodental supplement, where it is dosed at 1 billion CFU per tablet to support oral and dental health, specifically contributing to the maintenance of normal teeth and gums. It is also included in the Lactibiane Immuno formulation for immune system support. As a probiotic, it works through the modulation of the microbiome and interaction with the host immune system. These products are typically formulated as chewable tablets and are categorized as dietary supplements rather than pharmaceutical drugs.
- Brand names
- Lactibiane BuccodentalLactibiane Immuno
- Other names
- Lactobacillus paracasei LA 802Lacticaseibacillus paracasei LA802
Beyond the preview
Go deeper on lacticaseibacillus paracasei LA802.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lacticaseibacillus paracasei LA802.